Development and progression of cancer cachexia: Perspectives from bench to bedside.
Development and progression of cancer cachexia: Perspectives from bench to bedside.
复制标题
DOI：
10.1016/j.smhs.2020.10.003
复制
发表时间：
2020-12
影响因子：
--
通讯作者：
Greene NP
中科院分区：
文献类型：
--
作者：
Lim S;Brown JL;Washington TA;Greene NP
癌症恶病质(CC)是一种以体重减轻、脂肪和肌肉质量减少为特征的破坏性综合征，影响大约80%的癌症患者，并导致22%-30%的癌症相关死亡。了解CC发生的潜在机制对于推进治疗CC和改善癌症预后至关重要。CC是一种多器官综合征，导致骨骼肌和脂肪组织广泛萎缩；然而，CC也可以损害其他器官，如肝脏、心脏、大脑和骨骼。相当多的CC研究集中在肌肉内发生的变化，但对其他器官系统中与癌症相关的损害研究不足。此外，肌肉以外的器官系统的代谢变化可能有助于CC的发生。因此，本综述的目的是从全身角度探讨CC过程中的退变机制。概述已知的关于癌症发生的代谢变化的信息对于开发和加强治疗CC的方法是必要的。由于目前在CC中的大部分证据来自临床前模型，我们应该注意到这里综述的大多数数据来自临床前模型。
Cancer cachexia (CC) is a devastating syndrome characterized by weight loss, reduced fat mass and muscle mass that affects approximately 80% of cancer patients and is responsible for 22%–30% of cancer-associated deaths. Understanding underlying mechanisms for the development of CC are crucial to advance therapies to treat CC and improve cancer outcomes. CC is a multi-organ syndrome that results in extensive skeletal muscle and adipose tissue wasting; however, CC can impair other organs such as the liver, heart, brain, and bone as well. A considerable amount of CC research focuses on changes that occur within the muscle, but cancer-related impairments in other organ systems are understudied. Furthermore, metabolic changes in organ systems other than muscle may contribute to CC. Therefore, the purpose of this review is to address degenerative mechanisms which occur during CC from a whole-body perspective. Outlining the information known about metabolic changes that occur in response to cancer is necessary to develop and enhance therapies to treat CC. As much of the current evidences in CC are from pre-clinical models we should note the majority of the data reviewed here are from pre-clinical models.
登录
查看更多内容
DOI：
10.1002/jcsm.12354
发表时间：
2018-10
期刊：
Journal of cachexia, sarcopenia and muscle
影响因子：
--
作者：
Brown JL;Lee DE;Rosa-Caldwell ME;Brown LA;Perry RA;Haynie WS;Huseman K;Sataranatarajan K;Van Remmen H;Washington TA;Wiggs MP;Greene NP
通讯作者：
Greene NP
DOI：
10.1038/nrneurol.2014.77
发表时间：
2014-06
期刊：
Nature reviews. Neurology
影响因子：
--
作者：
Bennett GJ;Doyle T;Salvemini D
通讯作者：
Salvemini D
DOI：
10.1002/jcsm.12232
发表时间：
2017-12
期刊：
Journal of cachexia, sarcopenia and muscle
影响因子：
--
作者：
Brown JL;Rosa-Caldwell ME;Lee DE;Blackwell TA;Brown LA;Perry RA;Haynie WS;Hardee JP;Carson JA;Wiggs MP;Washington TA;Greene NP
通讯作者：
Greene NP
影响因子：
4.6
作者：
Argilés JM;Stemmler B;López-Soriano FJ;Busquets S
通讯作者：
Busquets S
影响因子：
4.7
作者：
Bongaerts, G. P. A.;van Hatteren, H. K.;Wagener, D. J. Th.
通讯作者：
Wagener, D. J. Th.